Does Kaiser Permanente Cover Farxiga (Dapagliflozin)?

What Farxiga Is and Why Coverage Decisions Are Complicated

Farxiga is the brand name for dapagliflozin, an oral sodium-glucose cotransporter-2 (SGLT2) inhibitor manufactured by AstraZeneca. The FDA has approved it for three separate indications: glycemic control in type 2 diabetes, reducing the risk of cardiovascular death or worsening heart failure in adults with heart failure with reduced ejection fraction (HFrEF), and slowing the progression of chronic kidney disease (CKD) with or without type 2 diabetes [1, 2].

Each indication has its own clinical evidence base. The DAPA-HF trial (N=4,744, NEJM 2019) showed that dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 26% relative to placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) in patients with HFrEF [3]. The DAPA-CKD trial (N=4,304) demonstrated a 39% relative risk reduction in the composite of sustained decline in eGFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes compared with placebo [4].

Those numbers matter to an insurer because they justify placing a drug on formulary at all. Kaiser Permanente, as an integrated HMO, runs its own pharmacy and therapeutics (P&T) committee. That committee weighs trial data against cost, existing alternatives, and the ability of its employed-physician model to manage the prescribing pathway internally. The result is a coverage structure that differs significantly from commercial PPO plans. Learn more about Farxiga's FDA label.

Kaiser Permanente's Formulary Structure and Where Farxiga Sits

Kaiser Permanente operates a closed formulary. That means drugs not on the approved list are generally not covered, regardless of medical necessity claims made at the point of prescribing. Farxiga appears on the formulary in most Kaiser regions, but it is placed at a specialty or non-preferred brand tier that carries a higher cost-share than generic alternatives like metformin or empagliflozin generics when those become available.

Formulary tier placement varies slightly by region. Kaiser Northern California, Southern California, Mid-Atlantic, and Northwest each maintain independent formularies approved by their respective P&T committees. A drug that is Tier 3 (preferred brand) in one region may be Tier 4 (non-preferred brand) in another. At the time of writing, the majority of Kaiser regions place Farxiga at Tier 3 or Tier 4, meaning copays typically range from $60 to $120 per 30-day supply for members in standard commercial plans.

Members on Medicare Advantage plans through Kaiser face a separate formulary under Part D rules. CMS requires Medicare Part D plans to cover SGLT2 inhibitors with approved cardiovascular or renal indications, which means dapagliflozin for HFrEF or CKD is more reliably covered under Kaiser Medicare plans than under some commercial products. The 2023 ADA Standards of Care explicitly state: "For patients with T2D and established CVD, or indicators of high CVD risk, established kidney disease, or heart failure, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended" [5]. Kaiser's Medicare formulary teams cannot easily ignore that language when making coverage determinations.

The framework below summarizes the three coverage tracks Kaiser Permanente members are most likely to encounter based on indication:

Track A (Type 2 Diabetes): Formulary access with prior authorization after step therapy. Metformin at maximum tolerated dose is typically required first, sometimes alongside a GLP-1 agonist or sulfonylurea, before dapagliflozin will be approved.

Track B (Heart Failure with Reduced Ejection Fraction): Prior authorization required. Cardiology referral within the Kaiser system is standard. Because DAPA-HF evidence is strong and guideline support is unambiguous, approval rates are higher here than for the diabetes indication.

Track C (Chronic Kidney Disease): Prior authorization required with nephrology involvement. CKD staging documentation (eGFR, urine albumin-to-creatinine ratio) must accompany the request. DAPA-CKD data [4] and the 2022 KDIGO CKD guidelines, which recommend SGLT2 inhibitors in CKD patients with eGFR 20 to 45 mL/min/1.73 m², are strong supporting references.

Prior Authorization Criteria: What Kaiser Actually Requires

Prior authorization at Kaiser operates through an internal-only pathway. Your prescribing physician must be a Kaiser-employed provider. Outside providers cannot initiate a Kaiser PA. This is one of the most common reasons members hit a dead end early.

For the type 2 diabetes indication, Kaiser's PA checklist generally requires:

• Confirmed T2D diagnosis with HbA1c above a threshold (commonly >7.5% or >8.0%, though the exact cutoff varies by region)
• Documentation of metformin use at the maximum tolerated dose for at least 90 days
• Documentation of at least one alternative agent tried and failed (often a GLP-1 agonist or a sulfonylurea)
• Cardiovascular risk stratification (ASCVD 10-year risk score or existing ASCVD diagnosis)
• Prescriber attestation that the clinical benefit outweighs the cost of a non-preferred agent

For the HFrEF indication, Kaiser typically requires:

• Echocardiographic confirmation of reduced ejection fraction (EF <40%)
• Cardiology attestation from a Kaiser-employed cardiologist
• Documentation of stable guideline-directed medical therapy (ACE inhibitor or ARB/ARNI, beta-blocker, mineralocorticoid receptor antagonist unless contraindicated)

For the CKD indication, Kaiser typically requires:

• eGFR between 25 and 75 mL/min/1.73 m² at time of request (mirroring DAPA-CKD eligibility)
• Urine albumin-to-creatinine ratio above 200 mg/g
• Nephrology co-management note within the Kaiser system
• Documentation of optimized renin-angiotensin system blockade

The 2022 KDIGO Diabetes Management in CKD guidelines state directly: "We recommend treatment with an SGLT2 inhibitor in patients with T2D, CKD and eGFR >=20 mL/min/1.73 m²" [6]. Quoting this in your PA letter is not optional. It is the single clearest lever a prescriber has to move a borderline review toward approval.

Processing time for Kaiser PAs is nominally 5 to 14 business days for standard requests and 72 hours for urgent requests. In practice, missing a single document from the checklist restarts that clock.

Step Therapy at Kaiser Permanente for Farxiga

Step therapy, sometimes called "fail first," requires members to try and fail a cheaper medication before an insurer will cover a more expensive one. Kaiser applies step therapy to the diabetes indication more aggressively than to the cardiovascular or renal indications.

For type 2 diabetes, the standard step sequence Kaiser enforces is:

1. Metformin (generic, Tier 1) at maximum tolerated dose
2. A sulfonylurea (generic, Tier 1) or a GLP-1 agonist if cardiometabolic risk is high
3. Dapagliflozin (Farxiga) only after the above steps are documented as inadequate or contraindicated

Step therapy exemptions exist. Federal law prohibits applying step therapy when: a patient has previously been stabilized on the requested drug, the step therapy drug is contraindicated, or required step therapy is likely to cause adverse effects based on the patient's history. If your physician can document any of these conditions, step therapy can be bypassed at the PA stage rather than during an appeal.

Empagliflozin (Jardiance), another SGLT2 inhibitor in the same drug class, may sit at a preferred tier on some Kaiser formularies. Kaiser's P&T committee could require an empagliflozin trial before approving dapagliflozin in the diabetes indication. Mechanistically the two drugs are similar, but they are not clinically identical. DAPA-CKD enrolled patients with eGFR as low as 25 mL/min/1.73 m², while EMPA-KIDNEY data extends to eGFR 20 mL/min/1.73 m². If your physician believes dapagliflozin is specifically indicated based on trial eligibility matching your case, that distinction belongs in the PA letter.

How to Appeal a Kaiser Permanente Denial of Farxiga

Denials happen. The appeal process inside Kaiser has three sequential stages, and missing a deadline at any stage forfeits that option.

Stage 1: Internal Appeal (Grievance)

File within 60 calendar days of the denial notice. Submit through Kaiser Member Services, either online at kp.org or by calling the Member Services number on your insurance card. Your physician must submit a detailed letter of medical necessity. This letter should cite DAPA-HF [3], DAPA-CKD [4], the ADA Standards of Care [5], and the KDIGO 2022 guidelines [6] by name. The reviewer at this stage is still a Kaiser-employed physician, so the internal appeal succeeds most often when the prescribing physician's note is thorough and guideline-grounded.

Decision timeline: 30 calendar days for standard appeals, 72 hours for urgent appeals (defined as situations where waiting would seriously jeopardize health).

Stage 2: Independent Medical Review / IRO

If the internal appeal is denied, you have the right to request review by an Independent Review Organization (IRO). This right exists under both state law and the ACA for most fully-insured plans. Kaiser must submit all case documents to the IRO, which is staffed by board-certified physicians unaffiliated with Kaiser. IRO decisions are binding on Kaiser. For drugs with the level of guideline support that dapagliflozin has for CKD and HFrEF, IRO overturn rates nationally run between 30% and 50% depending on state [7]. Filing at this stage costs members nothing.

Stage 3: State Insurance Commissioner Complaint

If the IRO upholds the denial, members can file a complaint with their state's insurance commissioner. This route is slower (30 to 90 days) but creates a regulatory record. In California, the Department of Managed Health Care handles Kaiser complaints and has authority to impose fines for inappropriate denials.

Self-funded ERISA employer plans present a harder problem. If your Kaiser coverage comes through an ERISA self-funded employer, state IRO rules may not apply. In that case, ERISA's internal appeal process and federal court are the remaining options. Check your Summary Plan Description to determine whether your plan is fully insured or self-funded.

Manufacturer Savings Programs and Kaiser Permanente

AstraZeneca offers the Farxiga Savings Card, which can reduce out-of-pocket costs to as low as $0 per month for eligible commercially insured patients. The key word is eligible. Federal law prohibits using manufacturer savings cards when a drug is paid for by a federal program, meaning Medicare, Medicaid, TRICARE, or any federally funded plan. Kaiser Medicare Advantage members cannot legally use the AstraZeneca savings card for Farxiga.

Commercial Kaiser members (employer-sponsored or individual-market plans not funded by federal dollars) may use the savings card, but Kaiser's closed pharmacy network creates a practical barrier. The savings card is processed at the pharmacy point of sale. Kaiser pharmacies are internal to the system and are not always set up to process third-party manufacturer cards in the same way that retail pharmacies like CVS or Walgreens are. Some members have reported success; others have been told the card cannot be processed at their Kaiser pharmacy location.

If the savings card is unavailable, AstraZeneca's patient assistance program (Farxiga Assist) offers free or reduced-cost medication for uninsured or underinsured patients who meet income criteria. Household income must generally be below 400% to 600% of the federal poverty level, and Kaiser members with active drug coverage typically do not qualify unless coverage is formally denied.

Cash-pay price for dapagliflozin through GoodRx-affiliated pharmacies averages approximately $540 to $620 per month for a 30-day supply of 10 mg tablets. Generic dapagliflozin does not yet exist in the United States market as of mid-2025; AstraZeneca's composition-of-matter patent runs through late 2025, with potential formulation patents extending coverage further [8].

The Clinical Case for Dapagliflozin That Supports Coverage

Understanding why dapagliflozin has broad guideline support helps members and prescribers make stronger PA arguments.

In DAPA-HF (N=4,744), dapagliflozin reduced cardiovascular death or worsening heart failure events by 26% compared with placebo (hazard ratio 0.74; P<0.001). The benefit appeared within 28 days of starting treatment and was consistent across subgroups, including patients without diabetes [3]. Dr. John McMurray, the trial's principal investigator, stated in NEJM: "These findings support the use of dapagliflozin as a treatment for heart failure with reduced ejection fraction, regardless of the presence or absence of type 2 diabetes" [3].

In DAPA-CKD (N=4,304), dapagliflozin reduced the risk of the primary composite endpoint (sustained eGFR decline >=50%, ESKD, renal death, or cardiovascular death) by 39% relative to placebo (hazard ratio 0.61; 95% CI 0.51 to 0.72; P<0.001) [4]. The trial was stopped early by its data monitoring committee because the benefit was so clear.

For type 2 diabetes specifically, the DECLARE-TIMI 58 trial (N=17,160) showed that dapagliflozin reduced the rate of hospitalization for heart failure or cardiovascular death (4.9% vs. 5.8%; hazard ratio 0.83; 95% CI 0.73 to 0.95; P=0.005) and reduced the renal composite endpoint versus placebo, confirming cardiorenal benefits beyond glycemic control alone [9].

These three trials together form the backbone of what any Kaiser PA reviewer should be evaluating. When a prescribing physician's letter ties patient-specific data (EF, eGFR, HbA1c, ASCVD risk) directly to the DAPA-HF, DAPA-CKD, and DECLARE-TIMI 58 results and the current ADA or KDIGO guidelines, the probability of approval increases substantially.

What to Do If You Are Waiting for Approval

While a PA is pending or under appeal, two short-term options exist.

First, ask your Kaiser physician whether a 30-day trial supply can be dispensed as a bridge under a clinical exception process. Some Kaiser regions allow this for drugs with urgent cardiovascular or renal indications. Documentation of urgency must be explicit in the chart.

Second, consider whether a clinically appropriate alternative SGLT2 inhibitor is immediately available on Kaiser's formulary at a lower tier. Empagliflozin for HFrEF (EMPEROR-Reduced trial, N=3,730, hazard ratio 0.75 for the primary composite) [10] and canagliflozin for CKD (CREDENCE trial, N=4,401) [11] have comparable guideline endorsements. Starting on a covered alternative while appealing for dapagliflozin prevents a gap in therapy that could worsen a patient's clinical trajectory.

Third, document everything. Every phone call to Member Services, every fax confirmation, every denial letter, and every piece of clinical correspondence should be saved. IROs and insurance commissioners weigh the completeness of a member's procedural record when making binding decisions.